Innovative funding partner throughout the growth life-cycle

Latest developments

News, Portfolio 04/01/2022              

ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

ProQR Therapeutics N.V.  a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has amended its convertible debt financing…
News, Portfolio 21/12/2021              

AMRA Medical secures $5 million funding agreement with growth debt investor Kreos Capital

AMRA Medical, a ground-breaking digital health company and global leader in body composition analysis offering medical device and medical research services, announced today that it has signed a growth debt…
News, Portfolio 23/11/2021              

OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces it has entered into a EUR 10…

Subscribe to our mailing list

Get our newsletter, Kreos updates and information on our events right to your mailbox.

Market Leading Growth Debt Investor for +22 years

Kreos Capital provides innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.

For over 22 years, our sole focus has been to support our ambitious ecosystem with personal, adaptable and responsive financing through every stage of the growth life cycle – from entry level through to late-stage growth including pre and post-IPO.